[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-adenocarcinoma":620},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,48,90,126,157,180,205,237,278,306,327,354,382,405,428,454,481,504,527,554,575,599],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100594635","predictive-risk-factors-for-pancreatic-fistula-after-pancreaticoduodenectomy-100594635",false,"NCT07022015","Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy","Predictive Risk Factors for Postoperative Pancreatic Fistula After Pancreaticoduodenectomy for Malignancy.","POPF","Inclusion Criteria:\n\n* Patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas.\n* Patients meeting the curative treatment intent in accordance with clinical guidelines:\n\n  * No evidence of metastasis.\n  * Radiological non-involvement of superior mesenteric vein \\& portal vein.\n* American Society of Anesthesiologists (ASA) scores I \\& II.\n* Patients aged \\> 18 years.\n* Ability to understand and the willingness to sign a written informed consent document\n* Agreement to complete the study\n\nExclusion Criteria:\n\n* Unfit patients for surgery due to severe medical illness.\n* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.\n* Irresectable tumors in diagnostic laparoscopy.\n* History of other malignant disease.\n* Pregnant or breast-feeding women.\n* Patients with serious mental disorders.\n* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data.\n* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis\n* Patients refused to participate in the study.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. In this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (CR-POPF) in the preoperative, intraoperative and postoperative period in patients that underwent PD. The total number of 100 participants expected to be included in this research who underwent PD between 2025 and 2026.",[28,29,30,31,32,33,34],"Pancreas Cancer","Pancreas Neoplasm","Pancreatic Fistula","Pancreas Adenocarcinoma","Periampullary Cancer","Periampullary Carcinoma","Resectable Pancreatic Cancer","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-06-20",{"date":43,"type":22},"2026-10-20",{"name":45,"class":46},"Minia University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":71,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":47},"100614693","phase-2-trial-comparing-standard-of-care-therapy-with-and-without-sequential-cytoreductive-intervention-for-patients-with-metastatic-foregut-adenocarcinoma-and-undetectable-circulating-tumor-deoxyribose-nucleic-acid-ctdna-levels-100614693","NCT07282912","Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","OLIGOMETS","Inclusion Criteria:\n\n* Has a primary diagnosis of AJCC 8th Edition Stage IV esophageal or gastroesophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder adenocarcinoma, duodenal, and ampullary adenocarcinoma.\n\n  a) All participants must have confirmed histologic diagnosis of the primary tumor, which may be confirmed retrospectively by a radiologist if necessary.\n* Has a primary tumor that must be locally resectable or can be treated definitively. Primary tumors included are esophageal, gastric, duodenal, ampullary, pancreatic, cholangiocarcinoma, and gall bladder carcinoma. Primary tumors should be resectable or treatable with consolidative radiotherapy or ablative therapy such as microwave ablation or trans-arterial chemo\u002Fradioembolization (cholangiocarcinomas).\n* Has limited (2 sites) metastatic disease determined to be completely resectable or treatable with curative intention (see SOE) at the time of diagnosis. This includes:\n\n  1. Up to five pulmonary metastases amenable to wedge resection (maximum of three wedge resections) or lobectomy (single lobectomy) or consolidative radiation\u002Fablative therapy\n  2. Up to five hepatic metastases amenable to hepatectomy (segmentectomy, sectionectomy, sectorectomy, minor hepatectomy, not more than three segments), wedge resection requiring a minimum of 40% of liver parenchyma following resection based on future liver remnant or a combination of partial hepatectomy and microwave ablation or trans-arterial radioembolization (TARE).\n  3. Lymphatic metastases that are resectable or intervenable (limited to only two non-regional sites) (see Appendix 3).\n  4. Resectable peritoneal disease with a PCI of ≤6 and the ability to obtain a CC0 cytoreduction.\n  5. Distant metastasis must be limited to two of the above-mentioned sites (a-d).\n  6. If both pulmonary and liver metastasis are present (a, b), then a total of five lesions will be considered oligometastatic.\n* Patients with resected primary tumors can be included if they present with oligometastases at least six months after the completion of treatment of primary tumor with curative intent.\n* Has adequate organ function, as described below (see Appendix 4); all screening laboratory tests should be performed within 30 days prior to the first study intervention.\n* Patients must have had two concordant negative tissue informed ctDNA tests measured at different timepoints and with the second being within 45 days prior to enrollment.\n* Patients must have at least 4 months of prior effective systemic therapy.\n* Has hemoglobin ≥ 8 g\u002FdL.\n* Has ANC ≥ 1500\u002FuL.\n* Has platelet count ≥ 75000\u002FuL.\n* Has total bilirubin ≤ 1.5 times the upper limit of normal (ULN).\n* Has aspartate aminotransferase (AST) \\& alanine aminotransferase (ALT) ≤ 5 times ULN.\n* Has creatinine clearance ≥ 50 mL\u002Fmin.\n* Patient who is at least 18 years of age at the time of signing informed consent and less than 81 years of age at the time of signing informed consent.\n* Has an ECOG performance status score 0-1 (see Appendix 6) at the time of randomization.\n* A male participant must agree to use contraception (barrier birth control, abstinence) during the treatment period and for at least 95 days following completion, corresponding to time needed to eliminate any study intervention(s), and refrain from donating sperm during this period.\n* A female participant of childbearing age is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception (hormonal, barrier birth control, or abstinence) during the treatment period and for at least 95 days following completion. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nInformed Consent\n\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for the Foundation for Blood Research (FBR). However, the participant may participate in the main study without participating in the FBR.\n\nExclusion Criteria:\n\n* Has a positive urine pregnancy test within 3 days prior to randomization or treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\nNote: In the event that 3 days have elapsed between the screening pregnancy test and the first dose of study intervention, another pregnancy test (urine or serum) must be performed and must be negative for the participant to start receiving study medication.\n\n* Has hypoxia as defined by pulse oximeter reading \\\u003C92% at rest or requires intermittent or chronic supplemental oxygen.\n* Has developed progressive disease on current line of systemic therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past three years.\n\nNote: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n\n* Has known CNS metastasis and\u002For carcinomatous meningitis.\n* Has known osseous metastasis.\n* Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medially controlled arrhythmia stable on medication is permitted.\n* Has poorly controlled hypertension defined as SBP ≥150mmHg and\u002For DBP ≥90mmHg.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.\n* Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (severe dysphasia, bowel obstruction, malabsorption).\n* Has known malignant pleural effusion or previous malignant effusion previously treated at the time of enrollment.\n* Has histologic subtypes not included in the inclusion criteria (including esophageal squamous cell carcinoma, gastroenteropancreatic neuroendocrine tumors, hepatocellular carcinoma, etc.).\n* Has a primary tumor that is not amenable to the treatment modalities listed in section 3.\n* Has albumin level less than 3.0 g\u002FdL despite appropriate nutritional support. Diagnostic Assessments\n* Has detectable ctDNA at the time of enrollment.\n* Has an active infection requiring systemic therapy.\n* Has known active TB\u002FCOVID infection.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study intervention.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 95 days after the last study intervention.\n* Inability to receive chemotherapy and\u002For surgery and\u002For radiotherapy and\u002For ablative procedures due to medical\u002Finsurance reasons.\n* Requires emergency surgery due to bleeding, perforation, or obstruction.","80 Years",{"count":58,"type":22},54,[60],"PHASE2","This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.",[63,64,65,66,31,67,68,69,70],"Foregut Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Adenocarcinoma","Gastric Adenocarcinoma","Duodenal Adenocarcinoma","Ampullary Adenocarcinoma","Gallbladder Adenocarcinoma","Intra - and Extrahepatic Cholangiocarcinoma",[72,73,74,75,76,77,78,79,80],"Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","Oligometastasis","Esophageal adenocarcinoma","Gastroesophageal adenocarcinoma,","Gastric adenocarcinoma","Duodenal adenocarcinoma","Pancreatic\u002Fampullary adenocarcinoma","Gallbladder adenocarcinoma","Intra- and extrahepatic cholangiocarcinoma.","2026-06-17",{"date":83,"type":39},"2026-06-22",{"date":85,"type":39},"2026-06-02",{"date":87,"type":22},"2028-06",{"name":89,"class":46},"Yale University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":47},"100642818","phase-1-the-0504-in-patients-with-solid-tumors-100642818","NCT07646106","THE-0504 in Patients With Solid Tumors","NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors","Inclusion Criteria:\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n1. written informed consent obtained;\n2. both gender adult (≥ 18 years) patients;\n3. diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa);\n4. measurable metastatic disease or locally advanced unresectable tumors;\n5. have exhausted all EMA-approved treatment options;\n6. ECOG Performance Status graded as 0 or 1;\n7. patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement;\n8. adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment:\n\n   * Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis).\n   * Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor);\n9. adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment:\n\n   • Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin per 1.73 m2 according to the CKD-EPI formula.\n10. adequate bone marrow function as defined as:\n\n    * Hgb ≥ 9 g\u002FdL\n    * ANC ≥1.5x109\u002FL\n    * PLT≥100.0 x109\u002FL\n11. Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.\n\nExclusion Criteria:\n\nPatients will not be enrolled if they meet any of the following criteria:\n\n1. pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women;\n2. male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration;\n3. additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy;\n4. have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor;\n5. ECOG Performance Status \\> 2;\n6. had not tolerated previously administered Top1 inhibitor treatments;\n7. known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible);\n8. serious concurrent illness;\n9. Hgb \\\u003C 9 g\u002FdL;\n10. Transfusion dependent anemia with transfusion dependency of ≥3 months;\n11. Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments;\n12. Iron overload, hereditary hemochromatosis and similar;\n13. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;\n14. Prolonged QTc interval;\n15. Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;\n16. Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm;\n17. History of severe allergic or anaphylactic reactions to previous protein-based therapy;\n18. Currently receiving anticoagulation therapy with warfarin;\n19. Known history of HIV infection, unless all the following are applicable:\n\n    * receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention;\n    * CD4 T-cell count \\> 350 cells\u002FμL\n    * CD4 T-cell nadir (lowest historical count) \\> 350 cells\u002FμL, and • viral load confirmed as \\\u003C 50 copies\u002FmL.\n20. HBV infection, unless on stable anti-viral therapy for \\> 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable;\n21. Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease;\n22. Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension;\n23. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations;\n24. History of drugs and\u002For alcohol abuse;\n25. Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and\u002For surgical procedures or other medical or ethical reasons);\n26. Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups;\n27. Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs\u002Fproducts up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs\u002Fproducts under investigation\\*\\*); or previous participation in the same trial or planned to receive other investigational products during the study.",{"count":98,"type":22},30,[100],"PHASE1","Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.",[103,104,105,106,31],"Small Cell Lung Cancer (SCLC)","Colorectal Carcinoma (CRC)","Gastric Cancer (GC)","Triple -Negative Breast Cancer",[108,109,110,111,112,113,114,115],"THE-0504","Solid tumors","Cancer","Single-centre","Thena Biotech","Italy","Phase 1","Europe","2026-06-09",{"date":118,"type":39},"2026-06-12",{"date":120,"type":39},"2024-11-13",{"date":122,"type":22},"2027-05-01",{"name":124,"class":125},"Thena Biotech S.r.l.","INDUSTRY",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100550778","phase-1-this-is-a-phase-1-trial-of-zm008-an-anti-llt1-antibody-used-as-single-agent-followed-by-combination-treatment-with-toripalimab-in-patients-with-advanced-solid-tumors-100550778","NCT06451497","This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors","Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Toripalimab in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Adult patients aged 18 years and older, at the time of signing the informed consent form.\n2. Part 1: Patients with histologically confirmed diagnosis of advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors that have no standard therapeutic option with a proven clinical benefit or are intolerant to these therapies with the following selected tumor histologies: NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, prostate cancer, colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, high grade serous ovarian cancer, diffuse large B cell lymphoma, kidney cancer, or urothelial cancer. This selection corresponds to tumor histologies known to express higher LLT1 levels. Other tumor histologies can be enrolled only if approved by the sponsor after discussion with the investigator. Tumors should be progressing or deserving another anticancer treatment in the opinion of the investigator. Part 2: The same patient population as Part 1 although it will be enriched or modified based on the observed antitumor activity observed in Part 1. In case the patient population is modified to include patients with standard therapeutic alternatives, a substantial amendment will be issued.\n3. Patients with tumors with actionable mutations should have progressed to all approved targeted therapies or have them contraindicated.\n4. The patient has measurable disease with RECIST 1. 1 on computed tomography (CT), positron emission tomography (PET)\u002FCT, or magnetic resonance imaging (MRI) scan. Imaging tests outside the screening period are valid if performed not more than 3 weeks before consent signature and otherwise fulfill protocol criteria. Patients with non-measurable disease may be allowed in Part 1 only with the explicit approval of the trial Medical Monitor.\n5. The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. Patients with renal cell carcinoma (RCC) to be allocated to a backfill cohort in Part 1 can have PS ≤2.\n6. The patient has adequate hematologic function as defined by:\n\n   1. Hemoglobin ≥9 g\u002FdL (whole or partial blood transfusions not allowed in the two previous weeks).\n   2. Absolute neutrophil count (ANC) ≥1.0 × 109\u002FL (growth factors like granulocyte colony-stimulating factor are not allowed in the two previous weeks).\n   3. Platelet count ≥75 × 109\u002FL (platelet transfusions are not allowed in the two previous weeks).\n7. The patient has adequate hepatic function as defined by:\n\n   1. Total bilirubin ≤1.5 times upper limit of normal (ULN).\n   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 times ULN, (if liver metastases are present, then ≤5.0 times ULN is allowed).\n   3. The patient has adequate renal function as defined by: estimated creatinine clearance (CrCL) using the Cockcroft- Gault formula ≥30 mL\u002Fminute.\n8. Women of childbearing potential (WOCBP) and men with sexual partners who are WOCBP must consent to adhere to contraceptive requirements as detailed in the protocol from the day of the signature of the informed consent to at least 4 months after the last dose of trial treatment.\n9. Suitable venous access for safe drug administration and the trial-required drug concentration and pharmacodynamic sampling.\n10. Permission to access archival biopsy located at the treating site or elsewhere. Note: Archival tissue does not need to be checked before Cycle 1 Day 1. The most modern archival biopsy is requested. If no archival tissue is available, the patient can still be enrolled in the escalation phase but not in Part 2.\n11. Pretreatment fresh biopsy is highly encouraged in Part 1 dose escalation once BED has been achieved. In Part 2, fresh pre-treatment and on-treatment biopsies should be obtained unless biopsy is associated with significant risk or declined by the patient and per discussion with the sponsor medical monitor (or designee).\n\nExclusion criteria:\n\n1. Patients should have recovered from toxicity related to previous anticancer treatments (including surgery and radiation) to Grade 0\u002F1 or baseline (except alopecia and peripheral neuropathy). Patients with endocrinopathies should have the replacement treatment in stable dosing.\n2. The patient has a history of uncontrolled brain metastasis. Patients with brain metastases are allowed if they are previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery and have new brain imaging confirming that brain metastasis are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either MRI or CT) and considered controlled with \\\u003C10 mg\u002Fday prednisone equivalent at the time of receiving the first dose of ZM008. For asymptomatic patients, screening brain imaging is not required.\n3. The patient has received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation for palliation), and who has not recovered to Grade ≤1 or baseline from related side effects of such therapy (except for alopecia).\n4. The patient had an active infection requiring parenteral or oral antibiotics at the time of the first dose. Patients receiving oral antibiotics can be enrolled after discussion and approval of the trial Medical Monitor.\n5. The patient has evidence of serious uncontrolled medical disorder that, in the opinion of the investigator or Medical Monitor, makes it unwise for the patient to participate in the trial or that might jeopardize compliance with the protocol.\n6. The patient has a psychiatric illness\u002Fsocial circumstance that would limit compliance with trial requirements and substantially increase the risk of AEs or has compromised ability to provide written informed consent.\n7. The patient has clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers.\n8. The patient has uncontrolled or significant cardiovascular disease defined as New York Heart Association classification III or IV.\n9. The patient has baseline QTc (using the Fridericia correction calculation) \\>470 msec in patients without pacemaker. Active autoimmune disease that is requiring systemic treatment (i.e., with use of disease modifying agents, corticosteroids at \\>10 mg\u002Fday of equivalent prednisone, or immunosuppressive drugs at any dose). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Participants with adrenal insufficiency on oral steroid replacement are allowed to participate in the study. Participants with controlled type I diabetes mellitus on stable insulin regimen are also eligible for the study. Participants with rheumatoid arthritis or psoriasis may be eligible if they have not experienced a flare in 2 years and do not require systemic therapy within the past year. Participants with vitiligo are also eligible.\n10. Use of therapeutic immunosuppressive medication (eg, prednisone dose of ≥ 10 mg\u002Fday or equivalent, tumor necrosis factor inhibitors at any dose) within 28 days prior to the first planned dose of study treatment. This does not include intranasal, intraocular, inhaled corticosteroids, topical and intra-articular joint injections, or physiologic replacement doses of systemic corticosteroids. Less than 10 mg prednisone per day or equivalent, short term, is allowed.\n11. For patients in the ZM008 monotherapy and combination arms: Patients who discontinued prior treatment with any immune checkpoint due to immune-related AEs, irrespective of grade, recovery, or need for continued steroid therapy. Also, patients without formal contraindication due to previous irAE are not eligible if the AE has not resolved to Grade 1 or better and\u002For still requires steroids (\\>10 mg of prednisone equivalent per day) for ongoing management.\n12. History of interstitial lung disease\u002Fnon-infectious pneumonitis, including immune-related pneumonitis of any Grade, radiation pneumonitis, active pulmonary tuberculosis, or evidence of active pneumonitis on screening chest CT scan. Participants with radiation therapy to the lung that is \\>30 Gy within 6 months of the first dose of treatment are excluded. Participants with active lung infections requiring treatment are also excluded.\n13. The patient has live vaccines reception within 30 days of enrollment.\n14. Known active hepatitis B or C.\n15. Patients positive for human immunodeficiency virus (HIV) can be enrolled only in Part 2 of the trial, but HIV-positive patients must meet the following criteria: a. have CD4+ T cell (CD4+) counts ≥350 cells\u002FμL. b. have not had an opportunistic infection within the past 12 months. Patients on prophylactic antimicrobials can be included in the trial. c. should be on established antiretroviral therapy for at least 4 weeks. d. have an HIV viral load of less than 400 copies\u002FmL prior to enrollment. e. known history of any other relevant congenital or acquired immunodeficiency other than HIV infection.\n16. Has known or suspected allergy to trial treatment, excipients, or related products.\n17. Prior allogeneic bone marrow transplantation or solid organ transplantation.\n18. Toripalimab cohort only: Any contraindication present in the toripalimab prescribing information.",{"count":21,"type":22},[100],"This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.",[137,138,31,139,140,141,142,143,144,145,146],"Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Biliary Tract Cancer","Prostate Cancer","Urothelial Carcinoma","Colorectal Cancer","Triple Negative Breast Cancer","High Grade Ovarian Serous Adenocarcinoma","Diffuse Large B Cell Lymphoma","Renal Cell Cancer Metastatic","2026-03-27",{"date":149,"type":39},"2026-04-02",{"date":151,"type":39},"2024-05-22",{"date":153,"type":22},"2027-04",{"name":155,"class":125},"Zumutor Biologics Inc.",3,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":47},"100502654","phase-2-neoadjuvant-chemotherapy-for-borderline-resectable-and-locally-advanced-pancreatic-adenocarcinoma-100502654","NCT05825066","Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Patients must have histologically or cytologically proven adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled\n* Patients with borderline resectable or locally advanced pancreatic adenocarcinoma as assessed per National Comprehensive Cancer Network (NCCN) guidelines (either pancreatic head, neck, uncinate process, or body\u002Ftail) or institutional multidisciplinary consensus\n* Age 18 or above\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1\n* Patients must have organ and marrow function as defined below:\n\nHemoglobin\\* ≥8 g\u002FdL Absolute neutrophil count ≥1,500\u002FmcL Platelets\\* ≥100,000\u002FmcL Total bilirubin\\* ≤1.5 X institutional upper limit of normal AST(SGOT)\u002FALT(SGPT) \\\u003C2.5 X institutional upper limit of normal Creatinine ≤1.5 X institutional upper limit of normal or CrCL\\>50\n\n* It is acceptable to transfuse packed red blood cells (PRBC) and platelets at the time of enrollment to meet the eligibility criteria.\n* If obstructive jaundice is present, consider ursodiol or a biliary drainage procedure. If the total bilirubin can be reduced or kept to less than or equal to 3 mg\u002FdL, then this inclusion criteria is met.\n\n  * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n  * Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative)\n\nExclusion Criteria:\n\n* Patients who have had prior chemotherapy with gemcitabine and\u002For nab-paclitaxel or FOLFIRINOX for pancreatic cancer\n* Patients receiving any other investigational anti-neoplastic agents\n* History of malignancy in last 3 years except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer, who are considered to be eligible\n* Patients with active and uncontrolled bacterial, viral or fungal infection requiring systemic therapy. Patients can be reevaluated for the study if the infection is deemed to be under control and the systemic therapy for the infection is completed\n* Uncontrolled intercurrent illness including, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the patient's safety\n* Patients with known diagnosis of interstitial lung disease, sarcoidosis, pulmonary fibrosis, or pneumonitis requiring oxygen supplementation. Those that do not require oxygen supplementation are eligible.\n* Patients who have undergone surgery, other than diagnostic or minor procedures, within 4 weeks prior to the initiation of study treatment\n* Patients who are pregnant or breastfeeding",{"count":165,"type":22},64,[60],"The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard chemotherapy for pancreatic cancer, has on participants and their condition. Gemcitabine - Abraxane (nab-Paclitaxel) and mFOLFIRINOX has been approved by the US Food and Drug Administration (FDA) as first line treatment for advanced pancreatic cancer. The sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX has not been approved by the FDA for treatment of pancreatic cancer.",[31,169,170],"Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","2026-03-23",{"date":173,"type":39},"2026-03-25",{"date":175,"type":39},"2023-08-01",{"date":177,"type":22},"2028-07",{"name":179,"class":46},"Wake Forest University Health Sciences",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100468193","assoc-of-genomic-polymorphisms-with-cancer-cachexia-in-subjects-with-panc-adenocarcinoma-100468193","NCT05376592","Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma","Association of Genomic Polymorphisms With Cancer Cachexia in Subjects With Pancreatic Adenocarcinoma","Inclusion Criteria:\n\nSubject must meet all of the following applicable inclusion criteria to participate in this study:\n\n* Written informed consent and HIPAA authorization for release of personal health information by the subject in accordance with the practices of the Levine Cancer Institute and Atrium Health. NOTE: HIPAA authorization will be included in the informed consent.\n* Male or female patients age ≥ 18 years at the time of consent\n* Histological or cytological confirmation of pancreatic adenocarcinoma, with a diagnosis of locally advanced unresectable PDAC (LAPC) or metastatic pancreatic adenocarcinoma. LAPC is defined as per NCCN 16. Note: Subject can be enrolled at any time during their cancer course following histologic diagnosis.\n* Able to provide a blood or buccal sample.\n\nExclusion Criteria:\n\n* None",{"count":21,"type":22},"OBSERVATIONAL","A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Though there is overlap amongst the pathophysiologic studies evaluating CC in murine models of different tumor types, the high prevalence of CC within gastrointestinal (GI) malignancies and specifically PDAC suggest that dedicated studies evaluating polymorphisms in candidate genes specific to PDAC warrant further evaluation. The collection and analysis of specimens under this study will facilitate the identification and characterization of genomic polymorphisms associated with CC in PDAC patients. Subsequently, this data may help contribute towards diagnostic and therapeutic treatments that may improve patient outcomes.",[31,191],"Cachexia",[193,194,195],"Cancer Cachexia","Wasting Syndrome","Pancreatic Cancer","2026-01-20",{"date":198,"type":39},"2026-01-22",{"date":200,"type":39},"2022-06-17",{"date":202,"type":22},"2031-01",{"name":179,"class":46},2,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":47},"100360753","phase-2-tumor-subtypes-in-subjects-on-folfirinox-with-non-metastatic-pancreatic-cancer-100360753","NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease.\n* Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.\n* Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core biopsy of the pancreatic mass.\n* Measurable or non-measurable but evaluable (as determined by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) resectable, borderline resectable or unresectable locally advanced PDAC.\n* Subject has adequate performance status as defined by ECOG performance status 0 or 1.\n* Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.\n* Age ≥ 18 years of age.\n* Subject has adequate organ function at study entry.\n* Subject has life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Subject has any evidence of local recurrence or metastatic pancreatic cancer.\n* Other malignancies within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n* Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their excipients.\n* Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.\n* Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association (NYHA) Class III or IV heart disease\n  * Active infection requiring IV antibiotics\n* Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1\\*28 polymorphism (baseline testing not required).\n* Subject has sensory peripheral neuropathy grade ≥ 2.\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.\n* Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.\n* Subject is pregnant or lactating.\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.","99 Years",{"count":214,"type":22},45,[60],"This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.\n\nChemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.\n\nResearchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.\n\nDepending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.",[218,219,220,31,221,222,223],"Pancreatic Ductal Adenocarcinoma (PDAC)","Cancer of Pancreas","Pancreatic Cancer, Adult","Pancreatic Neoplasms","Pancreatic Cancer Non-resectable","Pancreatic Cancer Resectable",[225,222,223,226,227,220],"Pancreatic Ductal Adenocarcinoma","neoadjuvant FOLFIRNOX","FOLFIRINOX","2026-01-09",{"date":230,"type":39},"2026-01-13",{"date":232,"type":39},"2019-06-12",{"date":234,"type":22},"2030-01",{"name":236,"class":46},"UNC Lineberger Comprehensive Cancer Center",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":249,"conditions":250,"keywords":260,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":47},"100613159","phase-4-preventing-postoperative-complications-in-patients-undergoing-high-risk-pancreatoduodenectomy-with-a-bundle-approach-including-hydrocortisone-octreotide-and-the-teres-ligament-patch-panenca-100613159","NCT07262957","Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA): an International Randomized Controlled Multicenter Trial","PANENCA","Inclusion Criteria:\n\n* Elective pancreatoduodenectomy for any indication (both minimally invasive and open)\n* Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI\\*\n* 18 years of age or older\n* Signature of informed consent\n* In the opinion of the investigator, the patient is eligible for the administration of hydrocortisone and octreotide, based on contraindications, warnings, and precautions as listed in the respective SmPCs\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy or current breastfeeding\n* Known allergy or hypersensitivity to hydrocortisone or octreotide\n* Systemic fungal infection\n* Concomitant use of strong CYP3A4 inhibitors or moderate-to-strong inducers that cannot be discontinued (see CYTOCHROME P450 DRUG INTERACTION TABLE (iu.edu))\n\n  * Inhibitors must be discontinued ≥7 days before randomization\n  * Inducers must be discontinued ≥28 days before randomization",{"count":246,"type":22},400,[248],"PHASE4","The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of the pancreas. One of the most frequent and serious complications after this surgery is postoperative pancreatic fistula (POPF), a leakage of pancreatic fluid from the surgical connection. POPF can lead to intra-abdominal infection, bleeding, and inflammation, often resulting in delayed recovery and postponement of subsequent oncological treatment. In severe cases, these complications may be life-threatening.\n\nPatients with a small main pancreatic duct (3 millimeters or less) are known to have a substantially higher risk of developing POPF. Previous studies have shown that several existing interventions may reduce the risk or severity of these complications. These include hydrocortisone, a medication that suppresses postoperative inflammation; octreotide, a medication that reduces the production of pancreatic secretions; and a surgical technique known as the ligamentum teres hepatis patch, which uses the patient's own tissue to protect nearby blood vessels in the event of a pancreatic leak.\n\nBecause the development of pancreatic fistulas is multifactorial, the investigators hypothesize that a combined approach targeting different underlying mechanisms may provide a complementary and more effective protective effect than any single intervention alone. The PANENCA trial therefore evaluates whether the combined use of hydrocortisone, octreotide, and the ligamentum teres patch can reduce the rate of major postoperative complications after pancreatoduodenectomy.\n\nPatients participating in the study are randomly assigned to receive either the combination treatment in addition to standard perioperative care or standard perioperative care alone. The study medications are administered only during the first postoperative days, and the surgical patch is applied during the operation itself. No additional tests, monitoring procedures, or hospital visits are required beyond routine clinical care.\n\nThis international, multicenter randomized trial includes patients at high risk for POPF who are undergoing pancreatoduodenectomy. The primary objective is to determine whether the combination treatment reduces the incidence of major postoperative complications. If proven effective, this bundle approach may be implemented more consistently across participating countries and incorporated into international clinical guidelines for pancreatic surgery.",[251,31,252,253,254,255,256,257,258,259],"Pancreas Head Cancer","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours","Pancreatitis",[261,262,15,263,264,265,266,267,268],"Whipple","Pancreatoduodenectomy","Major complications","Fistula","ISGPS","Hydrocortisone","Octreotide","Ligament teres patch","2025-12-16",{"date":271,"type":39},"2025-12-22",{"date":273,"type":39},"2025-09-01",{"date":275,"type":22},"2027-12-01",{"name":277,"class":46},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":47},"100596270","phase-2-24bro681--alternating-gnp-and-mfolfirinox-for-br-pdac-100596270","NCT07043270","24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisciplinary Tumor Board based on NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma.\n* Patients must be able and willing to provide informed consent.\n* Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.\n* ECOG Performance Status: 0-1.\n* Females of childbearing potential must have a negative pregnancy test done ≤ 14 days prior to study enrollment, and must agree to use a highly effective method of contraception throughout the course of protocol therapy.\n\nExclusion Criteria:\n\n* Any prior receipt of chemotherapy or radiation therapy for PDAC.\n* Known DPYD poor metabolizer genotype.\n* Known BRCA1\u002F2 or PALB2 mutations. If they are found to have BRCA1\u002F2 or PALB2 mutation after inclusion to the trial, the participant will be taken off of protocol therapy (since platinum-containing therapy is preferred for these patients).\n* Any confirmed second malignancy that is likely to require systemic therapy during the study period, in the opinion of the enrolling investigator.\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 7 g\u002FdL\n  * Creatinine \\> 1.5 x upper limit of normal (ULN)\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n* Any peripheral sensory neuropathy that meaningfully impairs performance of instrumental activities of daily living, as evaluated by the enrolling investigator.\n* Patients who are unable to provide informed consent.\n* Patients who are pregnant or breastfeeding.\n* Patients who are incarcerated.",{"count":286,"type":22},35,[60],"The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.",[31],[291,292,293,294,295,296,195],"mFOLFIRINOX","Gemcitabine","Nab-Paclitaxel","Neoadjuvant alternating chemotherapy","Resectable Pancreatic cancer","BR-PDAC","2025-10-16",{"date":299,"type":39},"2025-10-20",{"date":301,"type":39},"2025-09-29",{"date":303,"type":22},"2029-07-01",{"name":305,"class":46},"Dartmouth-Hitchcock Medical Center",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100323570","phase-2-testing-the-combination-of-two-approved-chemotherapy-drugs-and-radiation-prior-to-surgery-in-localized-pancreatic-cancer-100323570","NCT03492671","Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma","Inclusion Criteria (all criteria must apply):\n\n* Cytologic or histologic proof of adenocarcinoma of the pancreas.\n* Localized, potentially resectable tumors.\n* Greater or equal to 18 years of age.\n* ECOG performance status of 0 or 1.\n* Adequate hematologic, renal and hepatic function as defined by:\n* ANC greater or equal to 1,500 cells\u002Fmm3\n* Platelets greater or equal to 100,000 cells\u002Fmm3\n* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Serum creatinine ≤ 2 x ULN • ALT ≤ 5 x ULN\n* AST ≤ 5 x ULN\n* No history of prior therapy for pancreatic cancer.\n* No history of active infection requiring IV antibiotics at the start of study treatment\n* Non-pregnant and non-breast-feeding.\n\nExclusion Criteria:\n\n* Patient has borderline resectable or metastatic disease.\n* History of malignancy in the last 5 years other than in situ cancer or basal or squamous cell skin cancer or malignancies cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.\n* Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.",{"count":98,"type":22},[60],"The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.",[31,34],[195],"2025-09-30",{"date":320,"type":39},"2025-10-02",{"date":322,"type":39},"2019-07-17",{"date":324,"type":22},"2026-09",{"name":326,"class":46},"Loma Linda University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":47},"100599197","phase-3-neoadjuvant-vs-upfront-surgery-for-resectable-pancreatic-cancer-and-periampullary-cancer-100599197","NCT07081360","Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Histologically or cytologically confirmed pancreatic head cancer or periampullary carcinoma(endoscopic ultrasound (EUS)-guided biopsy).\n* Clearly resectable disease as defined by National Comprehensive Cancer Network (NCCN) criteria on cross-sectional imaging:\n\nNo involvement or abutment of the celiac artery, common hepatic artery, superior mesenteric artery, or replaced right hepatic artery .\n\nLess than 180 degree interface between tumor and vessel wall of the portal vein or superior mesenteric vein, and patent portal vein\u002Fsplenic vein confluence No evidence of metastatic disease.\n\n* Eastern Cooperative Oncology Group (ECOG)=0-1 \\& American Society of Anesthesiologists (ASA) score \\\u003C4.\n* Written informed consent.\n* Medical history without previous pancreatic resection or pancreatic cancer.\n* Adequate organ function (liver, kidney, bone marrow) (serum creatinine ≤2.0 mg\u002FdL,reference range 0.5-1.20 mg\u002FdL; serum albumin ≥2.5 g\u002FdL, reference range 3.5-5.3; aspartate aminotransferase (AST) ≤95 U\u002FL, reference range 0-38; Alanine aminotransferase (ALT) ≤102 U\u002FL, reference range 0-41; prothrombin time ≤1.8, reference range 0-1.20; partial thromboplastin time ≤1.8, reference range 0.82-1.25; leukocyte count greater than 3.5×109\u002FL, reference range 4.2-9.0; platelet count greater than 100×109\u002FL, reference range 130-400; hemoglobin ≥9 g\u002FdL, reference range 12-16).\n\nExclusion Criteria:\n\n* Borderline resectable or locally advanced pancreatic or periampullary cancer.\n* Tumor at the body or tail of the pancreas.\n* Distant metastases.\n* Prior chemotherapy , surgery or radiotherapy for pancreatic cancer.\n* Severe comorbidities precluding surgery or chemotherapy.\n* Pregnancy or lactation.\n* Other neoplastic diseases (malignant)diagnosed in the past 5 years.\n* Major surgery or traumatic event in the past 28 days.",{"count":335,"type":22},262,[337],"PHASE3","Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesions which are not being detected in early disease status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting.\n\nThere are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and periampullary cancer and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC and periampullary Cancer.\n\nThis randomized controlled trial compares neoadjuvant chemotherapy followed by surgery versus upfront surgery for patients with clearly resectable pancreatic head cancer and periampullary cancer. The study aims to determine if neoadjuvant chemotherapy improves overall survival compared to immediate surgery followed by adjuvant chemotherapy.",[28,32,340,223,341,31],"Periampullary Carcinoma Resectable","Ampullary Cancer",[343,344,345],"Pancreatic cancer","Neoadjuvant chemotherapy","Pancreaticoduodenectomy","2025-08-24",{"date":348,"type":39},"2025-08-29",{"date":350,"type":39},"2025-07-20",{"date":352,"type":22},"2028-08-20",{"name":45,"class":46},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":204},"100475437","genetic-testing-decision-aid-100475437","NCT05470920","Genetic Testing Decision Aid","Randomized, Controlled Trial of an Electronic Decision Aid for Genetic Testing in Inherited Cancer Syndromes","Inclusion Criteria:\n\n* 18 years or older\n* Being seen in clinic at Massachusetts General Hospital or Boston Medical Center\n* Diagnosed with malignant epithelial ovarian carcinoma or malignant pancreatic adenocarcinoma.\n\nExclusion Criteria :\n\n* Unable or unwilling to provide informed consent, undergo randomization, or complete the surveys associated with the study\n* Previous germline genetic testing\n* History of hereditary pancreatitis\n* Members of the following vulnerable populations: adults unable to consent, individuals who are not yet adults",{"count":362,"type":22},350,[25],"This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer",[366,31],"Epithelial Ovarian Carcinoma",[368,369,370,371,372],"pancreas adenocarcinoma.","epithelial ovarian carcinoma","decision aid","inherited cancer syndrome","genetic testing","2025-08-08",{"date":375,"type":39},"2025-08-13",{"date":377,"type":39},"2022-10-14",{"date":379,"type":22},"2026-12-31",{"name":381,"class":46},"Massachusetts General Hospital",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":47},"100406352","para-aortic-lymphnodes-removal-during-upfront-pancreaticoduodenectomy-100406352","NCT04571294","Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy","Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoa: Should it be Performed? A Multicentre Randomized Controlled Trial.","PALN","Inclusion Criteria:\n\n* pre-operative radiological or histological diagnosis of pancreatic head PDAC, including PDAC arising from IPMN (invasive-IPMN) (in case of not confirmation of PDAC at final pathological examination, the case will be considered as a \"drop out\" and excluded from the study);\n* upfront PD associated with standard lymphadenectomy.\n\nExclusion Criteria:\n\n* PD performed after neoadjuvant treatment;\n* PALN metastases diagnosed by a pre-operative PET-FDG (if performed);\n* intraoperative distant metastases;\n* R2 resection.",{"count":391,"type":22},180,[25],"Pancreaticoduodenectomy (PD) associated with lymphadenectomy is the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). In 2014, the International Study Group on Pancreatic Surgery (ISGPS) defined the \"standard lymphadenectomy\", that is mandatory during PD for PDAC. Lymphadenectomy should include the removal of the hepatoduodenal ligament nodes (stations 5, 6, 12b1, 12b2, 12c according the classification of Japanese Pancreas Society), nodes along the hepatic artery (station 8a), the posterior surface of the pancreatic head (station 13a and 13b), the superior mesenteric artery (14a right lateral side, 14b right lateral side) and nodes of the anterior surface of the pancreatic head (stations 17a and 17b). The inclusion of para-aortic lymphnodes (PALN) (station 16) in standard lymphadenectomy is still matter of debate. Moreover, some retrospectives or prospective studies reported that the presence of PALN metastases has a significant negative prognostic impact. Until now, no randomized studies comparing PD associated with standard lymphadenectomy with or without removal of PALN have been published. The aim of this study is to evaluate if the removal of station 16 should be routinely included in standard lymphadenectomy during PD for PDAC.",[28,395,31],"Pancreaticoduodenal Lymphadenopathy","2024-10-02",{"date":398,"type":39},"2024-10-04",{"date":400,"type":39},"2020-05-26",{"date":402,"type":22},"2025-05-31",{"name":404,"class":46},"Humanitas Hospital, Italy",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":412,"sex":17,"minAge":413,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":47},"100554337","the-application-of-dna-nanomachines-for-detecting-microrna-in-blood-for-the-diagnosis-of-pancreatic-cancer-diagnosis-of-pancreatic-cancer-100554337","NCT06497777","The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer","The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma\n* Proven by pathology\n* Patients who have not received anti-cancer therapies\n\nExclusion Criteria:\n\n* Less than 20 years old\n* Unable to provide inform and consent\n* Patients who have active malignancy other than pancreatic adenocarcinoma\n* Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing\n* Life expectancy less than 3 months",true,"20 Years",{"count":98,"type":22},"Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.",[31,417],"MicroRNA",[417,31],"2024-07-05",{"date":421,"type":39},"2024-07-12",{"date":423,"type":22},"2024-07-06",{"date":425,"type":22},"2026-06-01",{"name":427,"class":46},"National Taiwan University Hospital",{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":47},"100542931","pancreatic-cancer-and-synchronous-liver-metastases-resection-following-neoadjuvant-folfirinox-100542931","NCT06349278","Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX","Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX: a Prospective, Pilot Study","PDAC-LIV","Inclusion Criteria:\n\n* Confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC).\n* Resectable primary tumor based on triphasic CT-scan.\n* ≤ 3 liver metastases.\n* Liver resections can be performed by local excision or non-anatomical, partial hepatectomy. Patients with complete radiologic response after neoadjuvant FOLFIRINOX (FFX), therefore not requiring liver resection, will be included.\n* No evidence of extrahepatic metastases.\n* Patient fit for pancreatic resection (ECOG 0 or 1).\n* Stable or partial response on imaging after neoadjuvant FFX.\n* No new metastasis after neoadjuvant FFX\n* Blood tumor markers ≥ 80% decreased or within normal values after neoadjuvant FFX.\n\nExclusion Criteria:\n\n* Impossibility to obtain tissue diagnosis preoperatively confirming PDAC.\n* Locally advanced disease on triphasic CT-scan.\n* \\> 3 liver metastases.\n* Major hepatectomy required for liver metastases (right hepatectomy, left hepatectomy, central hepatectomy, extended right or left hepatectomy).\n* Suspicion or confirmation of extrahepatic metastases.\n* Patient unfit for pancreatic resection (ECOG 2 or more).\n* Contraindication to receive FFX.",{"count":437,"type":22},15,[25],"This is a prospective, pilot study from a single center. Patients will be evaluated and operated on by one of five surgeons with a subspeciality in hepato-biliary and pancreatic surgery. After thorough, standard of care assessment for both pancreatic primary and liver metastases resectability with blood tumor markers (CEA, CA 19-9 and CA-125), triphasic CT-scan and liver magnetic resonance imaging (MRI), patients with resectable pancreatic ductal adenocarcinoma primary and three or less resectable liver metastases will be prospectively included in the study. PET-scan may be added to the investigation depending on CT-scan or MRI results to prove metastatic disease or rule out extrahepatic metastases. Patients will receive a total of 12 cycles of perioperative FOLFIRINOX (FFX), with first reassessment with triphasic CT-scan to monitor tumor response after the first six cycles. Every patient will receive at least 6 cycles of FFX before surgery. The remaining six cycles will be received either preoperatively or postoperatively, depending on patient tolerance and tumor response at reassessment. Patients with liver metastases only visible on MRI will also have liver MRI at reassessment, which is also standard of care. Patients with evidence of tumor response on both imaging using RECIST V.1.1 criteria (stable disease or partial response), and blood tumor markers (≥ 80% decrease and\u002For normalization of all tumor markers) will then undergo pancreatic resection, either distal pancreatectomy or pancreatoduodenectomy depending on tumor side, with liver metastases excision. Each case will be followed with blood tumor markers and CT-scan every three months for two years, and every four months afterwards or until recurrence, which is standard of care for patients with metastatic PDAC. For patients without evidence of tumor response on imaging, or \\\u003C 80% decrease of all tumor markers, the standard palliative systemic treatment will be continued.",[31,441,28],"Pancreas Metastases",[443,444,343],"PDAC","Liver metastases","2024-04-12",{"date":447,"type":39},"2024-04-16",{"date":449,"type":39},"2024-01-16",{"date":451,"type":22},"2029-01-16",{"name":453,"class":46},"Laval University",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":412,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":47},"100514923","phase-2-nir-fluorescence-guided-surgical-resection-of-neoadjuvant-treated-localized-pancreatic-cancer-using-sgm-101-100514923","NCT05984810","NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101","A Performance Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for Fluorescence-guided Imaging to Determine Local Extent and Resectability During Surgical Resection of Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment","FLUOPANC-II","INCLUSION CRITERIA\n\nPart A: To be eligible for inclusion in this study, patients must meet all of the following criteria:\n\n1. Signed informed consent prior to any study-mandated procedure;\n2. Patients aged over 18 years old;\n3. Has the ability to communicate well with the Investigator in the Dutch\u002FEnglish language and willing to comply with the study restrictions.\n4. Neoadjuvant treated (borderline) resectable or locally advanced pancreatic cancer scheduled for a surgical resection\n\nPart B: To be eligible for inclusion in this study, healthy volunteers must meet all of the following criteria:\n\n1. Signed informed consent prior to any study-mandated procedure;\n2. Patients aged over 18 years old;\n3. Has the ability to communicate well with the Investigator in the Dutch\u002FEnglish language.\n\nEXCLUSION CRITERIA\n\nPart A: To be eligible for conclusion in this study, patients must meet none of the following criteria:\n\n1. History of clinically significant anaphylactic reactions;\n2. Previous administration of SGM-101;\n3. Pregnant women, or women giving breast feeding;\n4. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.\n\nPart B: To be eligible for conclusion in this study, healthy volunteers must meet none of the following criteria:\n\n1. Previous administration of SGM-101;\n2. Pregnant women, or women giving breast feeding;\n3. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.",{"count":463,"type":22},20,[60],"Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease. Complete surgical resection is the only potential curative treatment, however only a small percentage is eligible for upfront total surgical resection due to extension into anatomical related important vascular structures. Neoadjuvant chemo(radio)therapy has become the standard treatment modality for non-primary resectable disease (borderline resectable and locally advanced pancreatic cancer (LAPC)), where subsequent downstaging can make identification of the primary tumor more challenging during surgery. Near-infrared (NIR) fluorescence imaging can aid surgeons by providing real-time visualization of tumors, suspect lymph nodes and vital structures during surgery. Additional intra-operative feedback could possibly reduce the frequency of positive resection margins and increase complete removal of locally spread tumor and involved lymph nodes and could thereby improve patient outcomes as well as overall survival. SGM-101 is a targeted NIR-fluorophore, with specific binding capacity for Carcino Embryonic Antigen (CEA) which is overexpressed on tumor cells in the gastro-intestinal tract, including pancreatic cancer.",[31],[468,225,469,470,471],"Fluorescence Guided Surgery","Neoadjuvant therapy","Near-Infrared (NIR) Fluorescence imaging","CEA","2024-04-03",{"date":474,"type":39},"2024-04-04",{"date":476,"type":39},"2024-03-18",{"date":478,"type":22},"2026-12",{"name":480,"class":46},"Leiden University Medical Center",{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":47},"100528424","analyzing-and-solving-exceptional-long-term-survivors-in-solid-tumors-with-poor-prognosis-100528424","NCT06160596","Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis","Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study","ROSALIND","Inclusion Criteria:\n\nFOR SURVIVORS\n\n* To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:\n\n  1. Adult patient (≥18 years old at diagnosis).\n  2. Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.\n  3. Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt.\n  4. Availability of at least one block sample and associated clinical annotations with following characteristics:\n\n     * One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual\n     * Any treatment prior to sample acquisition must be reported - all treatments accepted (standard \u002F targeted);\n     * Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM\n\nFor CONTROL GROUPS :\n\n* To be eligible the control patients must fulfill the following inclusion criteria:\n\n  1. ≥18 years old at diagnosis.\n  2. Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer.\n  3. Paired to long-term survivors as mentioned in the methodology section\n  4. Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease\n  5. Availability of at least one tumor sample and associated clinical annotations with following characteristics:\n\n     * Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses\n     * Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard \u002F targeted).\n\n     Exclusion Criteria for both groups :\n* Patient must not be enrolled if he\u002Fshe fulfils one of the following non-inclusion criteria:\n\n  1. \\\u003C18 years old at diagnosis.\n  2. Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria.\n  3. Tumor sample not available or not reaching the required quality for multi-omic analyses.",{"count":490,"type":22},1020,"This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival.\n\nPatients with:\n\n* Cohort A: metastatic pancreatic ductal adenocarcinoma\n* Cohort B: glioblastoma IDHwt\n* Cohort C: extensive small cell lung cancer\n\nThis research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.",[31,493,494],"Small-cell Lung Cancer","Glioblastoma, IDH-wildtype","2023-11-29",{"date":497,"type":39},"2023-12-07",{"date":499,"type":39},"2023-11-01",{"date":501,"type":22},"2028-05-01",{"name":503,"class":46},"Cure 51",{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":388,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":526},"100521153","para-aortic-lymph-node-metastasis-in-resectable-pancreatic-cancer-100521153","NCT06065891","Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer","Prevalence and Consequences of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer: a Prospective Population Based Multicenter Study. The PALN Study","Inclusion Criteria:\n\nResectable suspected periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)\n\nBorderline resectable periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)\n\nAge \\>18 years\n\nWritten patient consent\n\nExclusion Criteria:\n\nContraindication for a radical resection procedure\n\nUnresectable tumor (NCCN guidelines 2020) or metastatic disease (lgll station 16 not included)\n\nMental or organic disorders which could interfere with giving informed consent or receiving treatments",{"count":512,"type":22},300,[25],"Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned.\n\nThe aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes.\n\nPrimary outcome\n\n1\\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection\n\nSecondary outcomes\n\n1. To determine prognosis of patients with PALN metastasis after a curative resection\n2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection.\n3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection.\n4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report.\n\n300 patients are planned to be included in the trial.",[28,31,516],"Lymph Node Metastasis","2023-09-26",{"date":519,"type":39},"2023-10-04",{"date":521,"type":39},"2023-09-05",{"date":523,"type":22},"2028-09-05",{"name":525,"class":46},"Jon Unosson",6,{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":412,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":536,"conditions":537,"keywords":542,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":47},"100520318","improving-pancreatic-cancer-care-by-the-use-of-computational-science-and-technology-100520318","NCT06055010","Improving Pancreatic Cancer Care by the Use of Computational Science and Technology","IMPACT","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients who received diagnostic procedures and\u002For treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)\n\nExclusion Criteria:\n\n\\- Subjects who object to the use of their data for the purpose of scientific research",{"count":535,"type":22},5000,"The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.",[195,538,539,540,31,541],"Pancreatic Cyst","Pancreatic Adenocarcinoma","Pancreatic Diseases","Pancreas Cyst",[543,544,545,195],"Artificial Intelligence","Data Science","Computer Science","2023-09-22",{"date":517,"type":39},{"date":549,"type":39},"2014-01-01",{"date":551,"type":22},"2029-12-31",{"name":553,"class":46},"UMC Utrecht",{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":564,"conditions":565,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":47},"100439150","safety-of-cyberknife-in-patients-with-borderline-resectable-or-locally-advanced-pancreatic-adenocarcinoma-100439150","NCT04998552","Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma","Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial","Inclusion Criteria:\n\n* Able to sign the informed consent and understand the consenting process\n* Completed neoadjuvant chemotherapy regimen\n* Patient is 18 years of age and older\n* Eastern Cooperative Oncology Group (ECOG) Status of 0-1.\n* Patient has a diagnosis of Stage I to Stage III pancreatic cancer cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria and NCCN guidelines, based on radiographic imaging or exploratory laparoscopic surgery, low degree of arterial involvement (CA, CHA, SMA) and no aorta involvement.\n* Patients who are deemed eligible for IMRT or SBRT and approved to receive radiation therapy by multidisciplinary tumor board\n* Patient shows no evidence of disease progression to distant metastasis based on NCCN.\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Pregnant or lactating female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of radiation therapy.\n* Resectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-2)\n* Unresectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-6)\n* Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade.\n* Patients with implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity.\n* Life expectancy of \\\u003C 1 year",{"count":562,"type":22},10,[25],"The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.",[31],"2023-03-30",{"date":568,"type":39},"2023-03-31",{"date":570,"type":39},"2021-06-22",{"date":572,"type":22},"2027-06-22",{"name":574,"class":46},"Capital Health System, Inc",{"id":576,"slug":577,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":47},"100466615","survival-quality-of-life-and-resectability-in-locally-advanced-pancreatic-cancer-100466615","NCT05356039","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study","SQUARE","Inclusion Criteria:\n\n* Confirmed or suspected invasive pancreatic primary tumor\n* Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines\n\nExclusion Criteria:\n\n* Suspected endocrine tumor\n* Suspected non-pancreatic periampullary tumor\n* Distant metastasis\n* Age \\\u003C 18 years\n* Patient unable to understand verbal or written information interfering with informed consent or treatment\n* Mental or organic disorder interfering with informed consent or treatments",{"count":512,"type":22},"This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer",[28,29,586,31,587,588,589,170,169],"Pancreas Disease","Surgery","Chemotherapy Effect","Quality of Life","2022-11-23",{"date":592,"type":39},"2022-11-30",{"date":594,"type":39},"2022-04-19",{"date":596,"type":22},"2028-05",{"name":598,"class":46},"Umeå University",{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":607,"targetDuration":608,"studyType":188,"phases":4,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":47},"100370114","pacareg-a-multicenter-registry-trial-in-pancreatic-ductal-adencarcinoma-100370114","NCT04099134","PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma","PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma","PaCaReg","Inclusion Criteria:\n\n* Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)\n* Age =\\>18 years\n* written informed consent\n\nExclusion Criteria:\n\n* papillary cancer\n* neuroendocrine pancreatic tumors",{"count":535,"type":22},"10 Years","PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma",[31,28],"2019-09-23",{"date":613,"type":39},"2019-09-25",{"date":615,"type":39},"2018-10-10",{"date":617,"type":22},"2029-10",{"name":619,"class":46},"University of Ulm","Pancreas, Adenocarcinoma"]